Subsequent bi-allelic SETD2 loss due to mutations could further contribute to tumor progression and metastasis by impacting H3K36me3-dependent processes such as MMR (via MSH6) and possibly mRNA processing. The gene discussed is SETD2; the disease is neoplasm.